Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

ABSTRACT:

Background

Dose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer (BC). Activating mutations in PIK3CA gene predict worse response to neoadjuvant chemotherapy for HER2-positive patients, while their role is less clearly defined for HER2-negative tumors.

Methods

We conducted a phase I/II study of neoadjuvant, sequential, dose-dense anthracycline/taxane chemotherapy, plus trastuzumab in HER2-positive patients and investigated the correlation of pre-treatment PIK3CA mutation status with pathologic complete response (pCR) and long-term outcome in a real-life setting.

Results

we established a dose-dense docetaxel recommended dose of 60 mg/m² and 65 mg/m², with or without trastuzumab, respectiv

SUBMITTER: Cocciolone V 

PROVIDER: S-EPMC6007957 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature